← Back

Wire · opportunities

FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High ...

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The US FDA has granted Breakthrough Therapy Designation to Daretabart for treating newly diagnosed high-risk neuroblastoma, aiming to accelerate development and review of this potentially impactful therapy.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You gain a shorter timeline to bring a new high-risk neuroblastoma treatment to market as FDA speeds development for breakthrough therapies like Daretabart. Accelerate your trial design and regulatory strategy to match this opportunity.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfdabreakthrough-therapyneuroblastomaoncologydrug-development